Kebilidi is the first gene therapy approved by the FDA for administration directly into the brain, given via a cannula during ...

The move reflects a growing interest in the PD-1 and VEGF pathways in the cancer space. Earlier this year, Summit ...

Complete enrollment in its DMT310 Phase 3 STAR-1 clinical trial in moderate-to-severe acne. Dermata expects to complete enrollment in the STAR-1 study by the end of 2024 and plans to announce topline ...

The Precision Health and Longevity Summit 2024, the first event of its kind in Canada, will take place on November 15-16, 2024, at The Westin Hotel in Calgary, Alberta. This groundbreaking event will ...

Capricor presented preclinical data at the 2024 American Association of Extracellular Vesicles (AAEV) Annual Meeting ...

Annual Invest in Greece Forum Series "Greece - Speeding Ahead Post Investment Upgrade" Monday, December 9, 2024 – New York Featuring Top US and International Investors, Global & Greek Companies, ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Conversations focused on Innovative Whole Health Strategies: Where Care, Science, AI And Economics Converge Judy Faulkner, Stéphane Bancel and Annie Lamont to Speak at 2024 Summit ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Serina Therapeutics, Inc. ("Serina") (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's ...